[go: up one dir, main page]

YU14002A - Mezoprogestini (progesteron receptor modulatori) za lečenje i prevenciju benignih hormonskih ginekoloških poremećaja - Google Patents

Mezoprogestini (progesteron receptor modulatori) za lečenje i prevenciju benignih hormonskih ginekoloških poremećaja

Info

Publication number
YU14002A
YU14002A YU14002A YUP14002A YU14002A YU 14002 A YU14002 A YU 14002A YU 14002 A YU14002 A YU 14002A YU P14002 A YUP14002 A YU P14002A YU 14002 A YU14002 A YU 14002A
Authority
YU
Yugoslavia
Prior art keywords
prevention
treatment
mesoprogestins
disorders
progesterone receptor
Prior art date
Application number
YU14002A
Other languages
English (en)
Inventor
Kristof Chwalisz
Walter Elger
Gerd Schubert
Original Assignee
Jenapharm Gmbh. & Co.Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm Gmbh. & Co.Kg. filed Critical Jenapharm Gmbh. & Co.Kg.
Publication of YU14002A publication Critical patent/YU14002A/sh
Publication of RS50283B publication Critical patent/RS50283B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Ovaj pronalazak obuhvata upotrebu mezoprogestina, nove klase progesteron receptor modulatora (PRM), za lecenje i prevenciju benignih hormonskih ginekoloskih poremecaja: a) za lecenje ginekoloskih poremecaja kao sto su endometritis, fibroidi materice, post operativne peritonalne priraslice, disfunkcionalna krvavljenja (metroragija, menoragija) i dismenoreja; b) za prevenciju ginekoloskih poremecaja kao sto su post operativne peritonalne priraslice, disfunkcionalna krvavljenja (metroragija, menoragija) i dismenoreja; c) postupak za lecenje i prevenciju gore navedenih poremecaja kod zenki, pozeljno kod zena, kojima je potrebno lecenje ili prevencija jednog ili vise od ovih poremecaja, sa efikasnom koliclnom mezoprogestina. Mezoprogestini su definisani kao jedinjenja koja poseduju i agonisticne i antagonisticne aktivnosti na progesteron receptor (PR) in vivo. Oni stabilizuju funkciju PR na srednjem nivou agonista i antagonista. Odgovarajuca funkcionalna stanja se ne mogu ostvariti progestinima ili antiprogestinima. Dnevna doza mezoprogestina je 0,5 do 100 mg, pozeljno 5 do 50 mg, a najpozeljnije 10 do 25 mg. J867, J912, J956 i J1042 su mezoprogestini pozeljni prema ovom pronalasku.
YUP-140/02A 1999-08-31 2000-08-31 Mezoprogestini za lečenje i prevenciju benignih ginekoloških poremećaja RS50283B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38614199A 1999-08-31 1999-08-31

Publications (2)

Publication Number Publication Date
YU14002A true YU14002A (sh) 2006-01-16
RS50283B RS50283B (sr) 2009-09-08

Family

ID=23524338

Country Status (34)

Country Link
EP (1) EP1229906B1 (sh)
JP (1) JP2003535029A (sh)
KR (3) KR100755109B1 (sh)
AR (1) AR025457A1 (sh)
AT (1) ATE375160T1 (sh)
AU (1) AU781840B2 (sh)
BG (1) BG65817B1 (sh)
BR (1) BR0014161A (sh)
CA (1) CA2382580C (sh)
CO (1) CO5200772A1 (sh)
CZ (1) CZ2002704A3 (sh)
DE (1) DE60036723T2 (sh)
DK (1) DK1229906T3 (sh)
EA (1) EA007854B1 (sh)
EE (1) EE05172B1 (sh)
ES (1) ES2295050T3 (sh)
HR (1) HRP20020267A2 (sh)
HU (1) HUP0202429A3 (sh)
IL (1) IL148416A0 (sh)
LT (1) LT5034B (sh)
LV (1) LV12941B (sh)
ME (1) MEP13808A (sh)
MX (1) MXPA02002191A (sh)
NO (1) NO20020999L (sh)
NZ (1) NZ517471A (sh)
PE (1) PE20010578A1 (sh)
PL (1) PL198790B1 (sh)
PT (1) PT1229906E (sh)
RO (1) RO122179B1 (sh)
RS (1) RS50283B (sh)
SI (1) SI20852B (sh)
SK (1) SK287192B6 (sh)
UA (1) UA78184C2 (sh)
WO (1) WO2001015679A2 (sh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1525215T3 (da) * 2002-08-02 2007-01-15 Schering Ag Modulatorer for receptoren for progesteron med forhöjet anti-gonadotrop aktivitet til fertilitetskontrol hos kvinder og ved terapi til erstatning af hormoner
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
US20040097591A1 (en) * 2002-11-18 2004-05-20 Kristof Chwalisz Use of selective progesterone receptor modulators for the treatment of androgen deficiency
RU2301691C1 (ru) * 2005-12-20 2007-06-27 Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Российской академии медицинских наук Способ восстановительного лечения женщин репродуктивного возраста с тазовыми перитонеальными спайками с фиксированной или субфиксированной ретродевиацией матки
DE102007011105A1 (de) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
RU2339392C1 (ru) * 2007-05-21 2008-11-27 Федеральное Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Росмедтехнологий Способ остановки маточных кровотечений в пубертатном периоде
US9592213B2 (en) * 2009-06-17 2017-03-14 National University Corporation Kumamoto University Prophylactic and/or therapeutic agent for dysmenorrhea
US8399432B2 (en) * 2009-10-27 2013-03-19 Lipogen Ltd. Compositions and methods of treatment for alleviating premenstrual syndrome symptoms
JP2022548314A (ja) * 2019-09-23 2022-11-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 妊娠を遷延させるためおよび月経または妊娠の合併症の処置の方法
US12426782B2 (en) 2020-11-06 2025-09-30 The Board Of Trustees Of The Leland Stanford Junior University Systems and temporal alignment methods for evaluation of gestational age and time to delivery

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3633244A1 (de) 1986-09-26 1988-03-31 Schering Ag Antigestagene zur hemmung der uterinen prostaglandinsynthese
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332284C2 (de) 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5576310A (en) * 1994-09-20 1996-11-19 Jenapharm Gmbh 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
US5693647A (en) * 1994-12-22 1997-12-02 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
DE69531998T2 (de) * 1994-12-22 2004-07-22 Ligand Pharmaceuticals, Inc., San Diego Steroidrezeptor-modulator verbindungen und methoden
SK282570B6 (sk) 1995-02-02 2002-10-08 Schering Aktiengesellschaft Antagonisty progesterónu na výrobu liekov na ošetrenie dysfunkčného maternicového krvácania
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
JP4260886B2 (ja) * 1996-05-01 2009-04-30 アメリカ合衆国 新規の抗プロゲステロンとしての２１―置換プロゲステロン誘導体
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
AU2708700A (en) * 1999-01-14 2000-08-01 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
AU4501800A (en) * 1999-05-04 2000-11-17 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods

Also Published As

Publication number Publication date
DE60036723T2 (de) 2008-07-17
SI20852A (sl) 2002-10-31
NO20020999L (no) 2002-03-14
PE20010578A1 (es) 2001-06-04
WO2001015679A3 (en) 2001-11-22
ES2295050T3 (es) 2008-04-16
CO5200772A1 (es) 2002-09-27
CZ2002704A3 (cs) 2003-02-12
AU6946600A (en) 2001-03-26
PL198790B1 (pl) 2008-07-31
LT2002031A (en) 2003-02-25
BG65817B1 (bg) 2010-01-29
NO20020999D0 (no) 2002-02-28
PT1229906E (pt) 2008-01-18
EP1229906B1 (en) 2007-10-10
HUP0202429A3 (en) 2004-04-28
SK287192B6 (sk) 2010-02-08
AU781840B2 (en) 2005-06-16
RS50283B (sr) 2009-09-08
EP1229906A2 (en) 2002-08-14
ATE375160T1 (de) 2007-10-15
MEP13808A (en) 2010-06-10
KR100864547B1 (ko) 2008-10-20
KR100755109B1 (ko) 2007-09-04
PL353930A1 (en) 2003-12-15
CA2382580A1 (en) 2001-03-08
LT5034B (lt) 2003-07-25
EE05172B1 (et) 2009-06-15
KR20080066095A (ko) 2008-07-15
IL148416A0 (en) 2002-09-12
JP2003535029A (ja) 2003-11-25
MXPA02002191A (es) 2002-09-30
KR20070058023A (ko) 2007-06-07
UA78184C2 (en) 2007-03-15
EA007854B1 (ru) 2007-02-27
EA200200282A1 (ru) 2002-10-31
LV12941B (en) 2003-06-20
KR20020027616A (ko) 2002-04-13
SK2992002A3 (en) 2002-07-02
NZ517471A (en) 2004-02-27
EE200200104A (et) 2003-04-15
BG106442A (bg) 2002-09-30
AR025457A1 (es) 2002-11-27
HUP0202429A2 (en) 2002-10-28
WO2001015679A2 (en) 2001-03-08
SI20852B (sl) 2009-06-30
CA2382580C (en) 2009-05-19
DK1229906T3 (da) 2008-02-11
DE60036723D1 (de) 2007-11-22
BR0014161A (pt) 2002-05-21
RO122179B1 (ro) 2009-02-27
HRP20020267A2 (en) 2004-04-30

Similar Documents

Publication Publication Date Title
AU703064B2 (en) Means and method for hormonal contraception and/or acne treatment
DK0792152T3 (da) Fremgangsmåder til svangerskabsforebyggelse
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
CA2084891A1 (en) Methods and formulations for use in inhibiting conception and in treating benign gynecological disorders
YU14002A (sh) Mezoprogestini (progesteron receptor modulatori) za lečenje i prevenciju benignih hormonskih ginekoloških poremećaja
ATE162712T1 (de) Verhuetungsverfahren mittels kompetitive progestronantagonisten und aehnliche neue verbindungen
YU54602A (sh) Drospirenon za terapiju zamene hormona
CA2182183A1 (en) Treatment of ovarian estrogen dependent conditions
HK1048761A1 (zh) 结合雌激素的选择性雌激素受体调节剂
MY118652A (en) Use of diazepines for preparing medicines for treating pathological conditions or diseases involving one of the growth hormone release inhibiting factor receptors
DK1488784T3 (da) Svangerskabsforebyggende implantat til mænd
WO2004000225A3 (en) Use of thio-oxindole derivatives in treatment of hormone-related conditions
CA2467237A1 (en) Method of preventing or treating benign gynaecological disorders
EP1079790A4 (en) BROAD SPECTRUM MICROBICIDE AND GERMICIDE COMPOSITIONS, DEVICES AND METHODS
WO2001064236A3 (en) METHODS FOR TREATING FSH RELATED CONDITIONS WITH GnRH ANTAGONISTS
WO1994008613A3 (en) Use of parathormone, of its biologically active fragments and of related peptides for treatment of pregnancy
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
WO2001026603A3 (en) Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
EA200200285A1 (ru) Мезопрогестины (модуляторы рецептора прогестерона) в качестве компонента композиций для заместительной гормональной терапии (згт)
WO2000059447A3 (fr) Utilisation d'hormones sexuelles pour l'obtention d'une composition pharmaceutique nasale utile pour le traitement des saignements uterins indesirables
WO2000032176A3 (en) Use of 17-ketosteroids for the treatment of toxoplasmosis and cryptosporidosis
WO2000066620A3 (en) Morphogen-induced enhancement of fertility
CA2219641A1 (en) Diagnostic composition